An observational study in Androgenetic Alopecia, sponsored by Cairo University. Not yet recruiting at 1 site in Egypt. Open to participants aged 12 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-20.
Sponsored by Cairo University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Alopecia with a site in Egypt — 9 open to participants now, 9 under way, 1 of them phase 3. Alopecia · Egypt.
Among the 25 studies in Alopecia with a site in Egypt, this one is one of 5 that started in 2026, is one of 4 observational ones, and was the 18th registered.
512 studies on the registry are indexed under Alopecia; 129 are open to participants now.
Browse Alopecia studies →9 of the 25 studies in Alopecia with a site in Egypt are open now. Recruiting first, the newest first:
Kasr El Aini Hospital · Sites in Egypt
Ages 18–50 · Men only · Healthy volunteers
Kasr El Aini Hospital · Sites in Egypt
Ages 18–50
Sohag University · Sites in Egypt
Ages 15–60 · Women only · Healthy volunteers
Sherief Ayman Hussein Shaamash · Sites in Egypt
Ages 18–40 · Men only
Assiut University · Sites in Egypt
Ages 18–50
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.
This study: 12 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 95 across 52 observational studies indexed under Alopecia.
Median enrollment 40 across the 21 interventional studies, 63 across the 4 observational. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 25 has an industry lead sponsor. The 10 most frequent:
Cairo University is the lead sponsor of 4,952 studies on the registry; 1,463 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
Cairo University has 7 studies filed under Alopecia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 25 studies in Alopecia with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to develop and validate deep learning models in diagnosis of male and female pattern hair loss, and assessment of its severity based on clinical and trichoscopic image by handheld dermoscopy and administrative data (age and sex).
The investigators intend to develop and validate artificial intelligence (AI) and machine learning (ML) models in diagnosis of male and female pattern hair loss, and assessment of its severity based on clinical and trichoscopic image using widely available and accessible handheld dermoscopes.
Conventional androgenetic alopecia (AGA) diagnosis and severity assessment are tedious and time-consuming tasks that are prone to human errors. These challenges can be tackled using artificial intelligence (AI), namely leveraging applications of machine learning and artificial neural networks for enhancing the diagnostic accuracy of scalp disease classification systems via dermoscopic image analysis. Computer aided assessment of hair microphotographs was attempted for decades, yet it faced many technical hurdles before the onset of deep learning and neural networks; and currently available software generate inaccurate results compared with visual counting. More accurate methods of analysis are needed for trichoscopic imaging, utilising deep learning image recognition models trained with a large image dataset. A number of deep learning models have been developed in recent years using videodermoscopy that achieved reliable hair density, thickness and severity classification, yet remain limited by small non-inclusive training datasets, need for hair shaving and lack of detailed reporting. Moreover, to our knowledge all previous models depend on image acquisition from expensive standalone videodermoscopy devices that lack widespread availability, rather than handheld dermoscopes that are commonly available.
The study will enroll 400 participants (200 healthy controls and 200 AGA patients). Controls undergo history and trichoscopic exams to exclude hair disorders. Trichoscopic examination will be conducted using a handheld dermoscope (CuTechs DS175) with a specialized field spacer. Patients will be assessed for disease severity using gender-specific scales. Both groups will have standardized digital and trichoscopic images taken for analysis. Images will be used to manually count and classify hairs, assess follicle units, and identify dermoscopic signs. A structured database will store all data and link clinical and image data to support objective diagnosis. AI models, particularly CNNs using transfer learning, will be trained on preprocessed images for classification and severity scoring. Model performance will be evaluated using metrics like accuracy, precision, recall, F1-score, and AUC-ROC compared with metrics reported by expert trichologists to validate accuracy and reliability
Patients diagnosed clinically and trichoscopically with androgenetic alopecia of both genders and apparently healthy controls.
for the patient group:
Inclusion criteria:
Exclusion criteria by clinical and trichoscopic examination:
for the control group: apparently healthy participants not suffering from the following: AGA, patchy hair loss, cicatricial alopecia, diffuse alopecia areata, inflammatory scalp disorders (psoriasis, seborrheic dermatitis, lichen planopilaris and frontal fibrosing alopecia in a pattern distribution).
Patients diagnosed clinically and trichoscopically with androgenetic alopecia of both genders. The diagnosis of AGA requires fulfillment of the primary criterion, plus one or more of the secondary criteria, and absence of exclusion criteria: * Primary criterion Hair shaft thickness heterogeneity on the frontal and/or vertex scalp, defined as proportion of hairs \< 0.06 mm (including intermediate, thin, and vellus hairs) ≥20%. * Secondary criteria 1. Proportion of single hair follicle unit on the frontal and/or vertex scalp ≥30%. 2. Proportion of vellus hairs on the frontal and/or vertex scalp \>10%. 3. There are at least two other dermoscopic signs: brown peripilar sign, yellow dots,white dots, scalp honeycomb pigmentation * Exclusion criteria Black dots, broken hairs, exclamation mark hairs
apparently normal participants not suffering from the following : 1. androgenetic alopecia 2. patchy hair loss. 3. cicatricial alopecia or diffuse alopecia areata 4. inflammatory scalp disorders (psoriasis, seborrheic dermatitis, lichen planopilaris and frontal fibrosing alopecia in a pattern distribution)
assessment of diagnostic capability of AI in AGA
Assess accuracy, sensitivity, specificity and positive predictive value of the trained AI models in differentiating AGA affected from non-AGA affected subjects using their macroscopic and trichoscopic images.
Time frame: 1 year
assessment of severity of androgenetic alopecia using AI
Assess accuracy, sensitivity, specificity and positive predictive value of the trained AI models in assessment of severity of androgenetic alopecia as regards: 1. Clinical classification (Sinclair scale for female pattern baldness and the Hamilton-Norwood scale for male pattern baldness) 2. Trichoscopic parameters: mean hair thickness (in micrometer, using planimetric analysis), hair density (frequency per cm2), proportion of terminal hairs, proportion of vellus hairs, number of hairs per follicular unit, presence of brown peripilar sign, yellow dots, and scalp honeycomb pigmentation.
Time frame: 1 year
facilitation of AI assessment using macroscopic imagies
To compare the model's diagnostic accuracy using the macroscopic versus trichoscopic images alone
Time frame: 1 year
Plan to share: Yes — relevant praticipant data shall be provided to researchers who request them on reasonable basis
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: from 2027 indefintely
Access criteria: access will be provided to deidentified data including all study parameters
Start is estimated for Apr 2026; primary completion for Sep 2026, 5 months later.
Of 18 observational studies under Alopecia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 38. This study's planned 5 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.